APOA5
-
Official Full Name
apolipoprotein A-V
-
Overview
Apolipoproteins are proteins that bind lipids (oil-soluble substances such as fat and cholesterol) to form lipoproteins. They transport the lipids through the lymphatic and circulatory systems. The lipid components of lipoproteins are insoluble in water. However, because of their detergent-like (amphipathic) properties, apolipoproteins and other amphipathic molecules (such as phospholipids) can surround the lipids, creating the lipoprotein particle that is itself water-soluble, and can thus be carried through water-based circulation (i.e., blood, lymph). Apolipoproteins also serve as enzyme cofactors, receptor ligands, and lipid transfer carriers that regulate the metabolism of lipoproteins and their uptake in tissues. -
Synonyms
UNQ411/PRO773; APOAV; RAP3; apo-AV; apolipoprotein A5; regeneration-associated protein 3;
- Recombinant Proteins
- Cell & Tissue Lysates
- Antibody
- Protein Pre-coupled Magnetic Beads
- Cattle
- Chicken
- Guinea pig
- Human
- Mouse
- Pig
- Rabbit
- Rat
- E.coli
- HEK293
- HEK293T
- In Vitro Cell Free System
- Mammalian Cell
- Mammalian cells
- Wheat Germ
- Flag
- FLAG
- GST
- His
- His (Fc)
- Avi
- His|GST
- Myc
- DDK
- N/A
- N
- Involved Pathway
- Protein Function
- Interacting Protein
- APOA5 Related Articles
APOA5 involved in several pathways and played different roles in them. We selected most pathways APOA5 participated on our site, such as Chylomicron-mediated lipid transport, Fatty acid, triacylglycerol, and ketone body metabolism, Lipid digestion, mobilization, and transport, which may be useful for your reference. Also, other proteins which involved in the same pathway with APOA5 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
Pathway Name | Pathway Related Protein |
---|---|
Chylomicron-mediated lipid transport | APOA4B.2;APOEA;APOC2;MTP;APOA1B;APOA5;APOBB.1;APOEB;APOA4A |
Fatty acid, triacylglycerol, and ketone body metabolism | ACOT6;AGPAT2;ACOT11B;ACOT7;Agmo;MED16;CYP7A1;ACOT8;CPT2 |
Lipid digestion, mobilization, and transport | APOA5;APOA1B;FABP11A;APOA4B.1;LMF2;FABP9;APOA4A;APOC2;CLPS |
Lipoprotein metabolism | APOA1B;APOA5;CETP;APOEA;APOBB.1;APOA4B.2;ABCA1;APOA4A;LPA |
Metabolism | KCNS3;ARSJ;OAZ1;ACY3.1;NDUFS7;MED8;SLC25A21;CTH;NAT2 |
Metabolism of lipids and lipoproteins | DHCR7;AKR1B15;GLTP;G0S2;ARSJ;CYP8B2;ACOT12;FABP9;AKR1C2 |
PPAR signaling pathway | PLIN1;ACSL3;ACSL4A;CPT1C;ACSL3A;ACSBG1;APOC3;ACADL;UBC |
PPARA activates gene expression | MED16;CDK19;MED20;MED8;MED18;MED25;MED15;G0S2;MED26 |
APOA5 has several biochemical functions, for example, cholesterol binding, cholesterol transporter activity, enzyme activator activity. Some of the functions are cooperated with other proteins, some of the functions could acted by APOA5 itself. We selected most functions APOA5 had, and list some proteins which have the same functions with APOA5. You can find most of the proteins on our site.
Function | Related Protein |
---|---|
cholesterol binding | OSBPL7;STARD6;PTCH1;OSBPL2;APOEB;APOA4B.1;APOEA;SYP;SOAT1 |
cholesterol transporter activity | ABCA7;ABCA1;APOA5;ABCA1B;ABCG4B;APOA4;ABCA4;APOB;APOA4B.2 |
enzyme activator activity | PRKCE;ASAP2;SFTPB;PRKCD;RICTOR;MMP17;ALDH1A2;UBA2;GLC8 |
enzyme binding | PAWR;YES1;MARCH6;DHCR24;TGFB1;TUT1;CRB2;NOXO1;PTPN1 |
heparin binding | APP;CCL8;FGF9;FGF4;UBE4A;OGN;CXCL11;ADAMTS3;HRG |
lipase activator activity | |
lipase binding | LRPAP1;GPIHBP1;FAF2;PLIN5;APOA5;APOB |
lipid binding | Ar;ALOX8;SH3GLB1;SH3GL3;PPARD;BPIFB1;CYTH4;SNX10B;S100A13 |
lipoprotein lipase activator activity | APOA5;APOC2;APOH |
lipoprotein particle receptor binding | Reln;LRP1;APOA5 |
low-density lipoprotein particle receptor binding | LDLRAP1;APOA5;LANCL1;SACS;CCDC167;APOEB;AP2M1;APOB;ARRB2 |
phosphatidylcholine binding | SERPINA5;ALDOB;APOA5;CHMP2A;VPS24;APOA4B.1;APOC1;CHMP3;APOA4 |
phosphatidylcholine-sterol O-acyltransferase activator activity | APOA4B.2;APOA4;APOEB;APOC1;APOA1;APOA2;APOA4B.1;APOA1A;APOEA |
phospholipid binding | PICALMA;PLA2G4C;ESYT1;ARHGAP44;NSMAF;APOEB;NBEAL2;APOE;MYOF |
APOA5 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with APOA5 here. Most of them are supplied by our site. Hope this information will be useful for your research of APOA5.
LPL; LPL; FAS; RAB5B; SMARCD1; q99ib8-pro_0000045598
- Q&As
- Reviews
Q&As (28)
Ask a questionWhile the primary role of APOA5 protein is in lipid metabolism, emerging research suggests its involvement in other physiological processes. It has been implicated in inflammation, insulin sensitivity, and energy metabolism, although the mechanisms and extent of these associations are still being explored.
APOA5 protein primarily interacts with chylomicrons and very-low-density lipoproteins (VLDL) in the bloodstream. It helps in the formation and clearance of these lipoproteins, which transport lipids, including triglycerides, throughout the body.
Yes, APOA5 protein has been linked to obesity. Certain APOA5 gene variants have been associated with higher triglyceride levels and an increased risk of obesity.
APOA5 protein plays a crucial role in the regulation of triglyceride levels, which are an important risk factor for cardiovascular disease. Variants in the APOA5 gene that lead to lower APOA5 protein levels or function have been associated with increased triglyceride levels and an increased risk of cardiovascular disease.
Ongoing research in APOA5 protein studies is focused on understanding the exact mechanisms by which APOA5 influences lipid metabolism, exploring the associations between APOA5 gene variants and various diseases, and investigating potential therapeutic strategies targeting APOA5 for the management of lipid-related disorders.
For individuals with APOA5 gene variations associated with increased triglyceride levels, a healthy lifestyle is generally recommended. This includes adopting a balanced diet that is low in saturated fat and high in fruits, vegetables, whole grains, and lean protein. Regular physical activity, weight management, and avoiding excessive alcohol consumption are also important factors in managing triglyceride levels.
Ongoing clinical trials and therapeutic interventions targeting APOA5 are limited, but several studies are exploring potential approaches. Some studies are investigating the use of gene therapy or gene editing techniques to modify APOA5 expression or function. Additionally, there are trials exploring the effects of drugs targeting other aspects of lipid metabolism, which may indirectly impact APOA5.
APOA5 gene variations primarily affect triglyceride levels, but they can also have some impact on cholesterol metabolism. Certain APOA5 variants have been associated with alterations in LDL cholesterol (bad cholesterol) and HDL cholesterol (good cholesterol) levels. However, the effects on cholesterol are generally less pronounced compared to their effects on triglycerides.
The prevalence of APOA5 gene variations varies across different populations. Some variants, such as the minor allele of rs662799, are relatively common, while others may be less prevalent. The exact frequency of APOA5 gene variations in the general population depends on various factors, including genetic ancestry and geographic location.
Currently, there are no specific therapeutic interventions targeting APOA5 protein available for clinical use. However, ongoing research is exploring the potential of modulating APOA5 levels or function as a therapeutic strategy for treating lipid-related disorders.
Yes, APOA5 protein levels can be measured in clinical settings using specific laboratory techniques. These measurements are often used in research studies to understand the role of APOA5 protein in lipid metabolism and its association with various diseases.
Studies have reported interactions between genetic variations in the APOA5 gene and factors like obesity, insulin resistance, and alcohol consumption, which can amplify the effect of APOA5 gene variations on triglyceride levels and the risk of cardiovascular diseases.
The modulation of APOA5 expression or function holds promise as a potential therapeutic strategy for cardiovascular diseases. Preclinical studies and limited clinical trials have shown that manipulating APOA5 levels or activity can have beneficial effects on lipid profiles and atherosclerosis development. However, further research is needed to fully establish the safety and efficacy of such interventions before they can be widely implemented.
Modulating APOA5 expression or function is still a developing area of research, and the potential side effects or risks are not yet fully understood. Gene therapy or gene editing approaches could have off-target effects or unintended consequences. Therefore, further research and careful considerations are needed to ensure the safety and efficacy of such interventions.
Yes, there are known genetic variants in the APOA5 gene. Some of these variants, such as the T-1131C and C56G variants, have been associated with alterations in APOA5 protein levels and triglyceride metabolism.
For individuals with APOA5 gene variations and high triglyceride levels, lifestyle and dietary interventions are generally recommended. This may include following a low-fat, low-sugar diet, reducing alcohol consumption, engaging in regular physical activity, maintaining a healthy weight, and managing other risk factors such as hypertension and diabetes. However, it is essential to consult with a healthcare professional for personalized advice tailored to an individual's specific situation.
Yes, genetic testing can be done to detect variations in the APOA5 gene. Various methods, such as DNA sequencing or genotyping, can identify specific variations or mutations in the gene. This information can help assess an individual's risk for certain lipid disorders and cardiovascular diseases.
Yes, certain genetic variants in the APOA5 gene have been associated with an increased risk of pancreatitis, a condition characterized by inflammation of the pancreas. Elevated triglyceride levels, influenced by APOA5 variants, may contribute to the development of pancreatitis.
APOA5 protein research provides insights into the genetic and molecular factors contributing to lipid metabolism and cardiovascular diseases. Understanding an individual's APOA5 gene variants and their impact on triglyceride regulation may contribute to personalized treatment plans, risk assessment, and preventive strategies tailored to an individual's genetic profile.
Yes, lifestyle factors such as diet and exercise can influence the expression and function of APOA5 protein. Certain dietary components, like omega-3 fatty acids, have been shown to upregulate APOA5 expression, while a high-fat diet or sedentary lifestyle may downregulate it.
Yes, variations in the APOA5 gene can influence other lipid parameters. Some studies have shown associations between APOA5 gene variants and levels of high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol, although the relationships are not as strong as those with triglycerides.
Yes, APOA5 gene variations can be inherited from parents. They can be passed down through family generations, contributing to a higher risk of developing certain lipid disorders or cardiovascular diseases. However, it is important to note that genetic variations alone do not determine disease risk and can interact with other genetic and environmental factors.
Some studies suggest that certain medications, such as statins (cholesterol-lowering drugs) and fibrates (used to treat high triglyceride levels), may affect APOA5 protein levels. However, more research is needed to fully understand these interactions and their implications.
Yes, variations in the APOA5 gene can influence an individual's response to lipid-lowering therapies. Some studies have shown that certain APOA5 gene variants may affect the efficacy of medications like fibrates in reducing triglyceride levels.
While the primary focus of APOA5 research has been on its involvement in lipid metabolism and cardiovascular diseases, there is also ongoing research into its potential role in other diseases and disorders. This includes conditions such as obesity, diabetes, and neurodegenerative diseases. Studies are exploring the complex interactions between APOA5 and various physiological processes to further understand its diverse functions.
While APOA5 protein levels have been studied as a potential biomarker for cardiovascular risk assessment, its clinical utility as a standalone biomarker is not yet well-established. It may have more value when combined with other lipid markers and risk factors for a comprehensive assessment.
Yes, mutations or changes in the APOA5 gene have been associated with certain lipid disorders and cardiovascular diseases. These include hypertriglyceridemia (high triglyceride levels), familial combined hyperlipidemia, metabolic syndrome, and an increased risk of coronary artery disease.
APOA5 protein interacts with enzymes involved in triglyceride metabolism, such as lipoprotein lipase (LPL), and affects their activity. It modulates the breakdown of triglycerides in circulating lipoproteins, influencing the levels of triglycerides in the blood.
Customer Reviews (4)
Write a reviewThe manufacturer of APOA5 protein has consistently provided outstanding technical support that has surpassed my expectations.
This protein demonstrates remarkable purity, stability, and specificity, ensuring utmost accuracy and reproducibility in my research endeavors.
I am delighted to express my complete satisfaction with the quality of APOA5 protein, as it precisely suits my experimental requirements.
Their dedication to customer satisfaction has been instrumental in overcoming obstacles and achieving successful results in my experiments.
Ask a Question for All APOA5 Products
Required fields are marked with *
My Review for All APOA5 Products
Required fields are marked with *